Compare Ascendis Pharma A/S (ASND) vs Target Corporation (TGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Target Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Target Corporation trades at $135.68 (market cap $61.38B). The key difference: Target Corporation is far larger — about 3.5× Ascendis Pharma A/S's market cap, and Target Corporation pays a 3.43% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TGT | |
|---|---|---|
Market Cap | $17.74B | $61.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $141.19 |
52-Week Low | $163.32 | $83.68 |
Enterprise Value | $18.11B | $76.68B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Target Corporation (TGT) trades at $135.13, up 2.19% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a P/E of 17.85, ROE of 22.02%, and positive cash flow trends. Recent corporate restructuring aims to streamline operations while maintaining dividend payments.
Target presents a balanced investment case with solid profitability and analyst consensus near current levels. Upside potential exists toward the $137 price target, though competitive pressures and margin compression remain key risks. The stock offers stability with dividend income but faces retail sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
